At the recent American Society of Clinical Oncology (ASCO) annual meeting, interim results from the DESTINY-Breast09 trial ...

In this video, Megan Kruse, MD, breast medical oncologist at Cleveland Clinic, discusses results from an interim analysis of the DESTINY-Breast09 trial, which were presented at ASCO Annual Meeting.The ...

Trastuzumab deruxtecan plus pertuzumab showed significant improvement in PFS compared with taxane chemotherapy plus ...

Dr. Sara M. Tolaney breaks down key takeaways from the DESTINY-Breast09 trial that patients with HER2+ advanced or metastatic ...

Fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) plus pertuzumab (Perjeta) significantly improved progression-free survival (PFS) compared with standard-of-care therapy in the first-line treatment of ...

This study provides compelling evidence that SLC7A11 may serve as a potential therapeutic target for trastuzumab-resistant HER2-positive breast cancer. While the findings are well-supported by robust ...

Due to a technical issue, this story was not posted in its entirety. It has been updated to include the missing portion. NEW YORK – A dual HER2-targeted combination of the antibody-drug conjugate ...

CHICAGO -- First-line trastuzumab deruxtecan (T-DXd) combined with pertuzumab (Perjeta) improved progression-free survival (PFS) in HER2-positive locally advanced or metastatic breast cancer ...

WILMINGTON, Del., June 02, 2025--Positive results from the DESTINY-Breast09 Phase III trial showed ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab demonstrated a highly statistically ...

Enhertu (fam-trastuzumab deruxtecan-nxki; T-DXd) combined with Perjeta (pertuzumab) as first-line treatment improved progression-free survival (PFS) versus standard care for patients with ...

In the trial, treatment with Enhertu and Perjeta delayed cancer growth for longer than the established regimen of Perjeta, Herceptin and chemotherapy, which is known by the acronym THP.

CHICAGO — Results from the phase 3 DESTINY-Breast09 clinical trial found that the combination of trastuzumab deruxtecan (Enhertu®) with pertuzumab (Perjeta®) can delay cancer growth for longer than ...